Biogen doubles down
Why Biogen says aducanumab deal amendments increase its upside in AD
Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched rare disease drug Spinraza nusinersen.
While the Street apparently interpreted changes to Biogen’s two deals covering aducanumab as an exposure to increased near-term costs and decreased revenue expectations, President and CEO Michel Vounatsos told BioCentury the amendments leave the biotech better positioned to reap value from its lead asset in Alzheimer’s disease, one of the four core growth areas for its neuroscience business...